Dr. Min ZHANG has over 18 years of experience in venture capital investment, start-up and public company operations, and biomedical research in the life sciences industry in China. She also has working knowledge in company strategy, reorganization, M&A, IPO preparation, and corporate compliance.

Dr. Zhang is primarily responsible for deal sourcing, due diligence, structuring, and portfolio management for early stage bio-pharmaceutical companies to growth stage medical device and healthcare service companies. Prior to Cenova, Dr. Zhang was the Board Secretary and Senior Director of the Executive Office at Shanghai Genomics, a life science company listed on the Tokyo Stock Exchange.

Dr. Zhang received her M.D. from Fudan University Medical School.

Mr. Frank FENG joined Cenova in 2017, serving as the Chief Financial Officer of the firm. He has extensive experiences in domestic and overseas public listing, company restructuring, and mergers and acquisitions. Prior to Cenova, Mr. FENG was the Chief Financial Officer of Suzhou Haowu and Ku6 Media (NASDAQ:KUTV), the Vice President of Finance at Taomee Holdings Ltd. (NASDAQ:TAOM) and the Director of Finance at Renesola Ltd. (NYSE: SOL). He was a financial auditor at Deloitte, PriceWaterhouseCoopers and KPMG for over 12 years. Mr. FENG became a member of the Chinese Institute of Certified Public Accountant in 1999 and received his Bachelor's Degree in Industrial Foreign Trade from Shanghai Jiaotong University in 1996.

Dr. Haohao ZHANG joined Cenova in 2012 and is primarily responsible for deal execution, portfolio management and divestments in biopharmaceuticals, medical devices and healthcare services companies. She has extensive experiences in RMB off-shore investments and has led the investments in ASLAN Pharmaceuticals (TWSE: 6497), Optomed, VIVACE Therapeutics and Lumo BodyTech.  

Prior to Cenova, Dr. Zhang was the Executive Scientific Assistant to the CEO of Shanghai Biomabs Pharmaceutical Co. Ltd., one of the leading antibody drug companies in China. At Biomabs, she coordinated the company's efforts in scientific due diligence, clinical development, regulatory compliance, and public relations.

Dr. Zhang received her Ph.D. in Cancer Pharmacology from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences and her M.D. with honors from the Medical School of Jinan University, Guangzhou.

Ms. Rui JIN joined Cenova in 2010 with over 12 years of combined life-science investment and biomedical research experience.  She is primarily responsible for deal screening, due diligence, deal structuring and portfolio management. Previously, Ms. Jin played a key role in fund management, investor relations and internal risk control for Cenova's existing RMB funds. Prior to Cenova, she was the Manager of Drug Registry and Business Development at Shanghai Genomics, a life science company listed on the Tokyo Stock Exchange.

Ms. Jin holds a Masters in Molecular Biology from Shanghai Normal University.

Mr. Phaniah WANG joined Cenova’s investment team in 2015. He has more than ten years of experience in mergers and acquisitions and public listings for healthcare services, biotechnology, pharmaceuticals, chemicals, and large manufacturing companies. Prior to Cenova, he was a Senior Manager at PwC Shanghai and Hong Kong, providing mergers and acquisitions advisory services for private equity firms, multi-national companies and Chinese state-owned enterprises. His clients included Sequoia, TPG, CVC, Medtronic, Warburg Pincus, China Investment Corporation, FountainVest and Zhangjiang Venture Capital Group. Prior to PwC, Phaniah was a Financial Manager at Ernst & Young (Shanghai), where he led a 60-member team to provide assurance services for A and H-share listed companies.

Phaniah is a CICPA, and he graduated from Zhejiang University with a Bachelor's degree in Management.

Mr. Xiaoyin SHEN joined Cenova in 2017 with nearly six years of experience in healthcare investment. Prior to Cenova, he worked at China Everbright Limited Healthcare Fund I & II, Dalian Yifang Group and Simon Murray Capital and invested in bio-pharmaceuticals, consumer health, diagnostics and healthcare services.  Some of the investments that he has made included BGI (SZ: 300676), Betta Pharma (SZ: 300558), Etong Healthcare, Ambrx, Amcare, Beijing Jingdu Children’s Hospital and Xiuzheng Pharmaceutical Group. Mr. Shen was previously a senior associate at the Corporate Finance division of PwC, providing financial advisory services for Chinese outbound investments.

Mr. Shen graduated with a B.A. and M.A. in Economics from Renmin University of China and University of Connecticut respectively. He was also the co-author and translator of a book, “Fair Trade for All”.

Ms. Emily YANG joined Cenova in 2018 and is primary responsible for financial due diligence, financial modelling and valuation analysis.

Prior to Cenova, Ms. Yang spent 5 years at Duff & Phelps, a global valuation and corporate finance advisory. In this role, she provided financial advisory analysis for mergers and acquisitions, cross-border joint ventures, financial reporting and tax restructuring across various industries including life science companies. Ms. Yang had also worked at a risk consulting firm and PwC providing risk management and audit services under PRC, IFRS and US GAAP.

Ms. Yang is a CFA charter holder and holds the ACCA qualification. She graduated with a Master in Investment Management from Cass Business School, and a Bachelor in International Accounting from Shanghai University of Finance and Economics.

Ms. Yang ZHOU joined Cenova in 2017, and is primary responsible for project due diligence and evaluation, project execution and portfolio management. Prior to Cenova, Ms. Zhou was an Associate at the life-science practice of L.E.K. Consulting, one of the leading global management consulting firms. She has worked on strategic planning,  drug pricing, market access, business growth, and due diligence projects for overseas and domestic healthcare companies and private equity firms.

Ms. Zhou graduated from the University of Southern California with a Bachelor of Science degree in Business Administration.

Mr. Anthony ZHANG joined Cenova Capital in 2019 and is primarily responsible for project due diligence and evaluation, project execution and portfolio management. Prior to Cenova, he was an associate at Ping An Capital, where he focused on last-stage private equity investments in healthcare sector. Before that, Mr. Zhang worked at BNP Paribas as a healthcare investment banking analyst.

Mr. Zhang holds a B. BA. (First Class Honor) degree from the Chinese University of Hong Kong in Finance.

Mr. Angus HE joined Cenova in 2019 and his primary responsibility includes project due diligence and evaluation, project execution and portfolio management. Prior to Cenova, Mr. He was an associate at Lincoln International, a U.S.-based boutique investment bank that focuses on cross-border M&A. Mr. He executed and closed several healthcare related projects in medicine distribution, pharmaceuticals, hospital management sectors.

Mr. He graduated with a BA. in Economics from Renmin University of China. Mr. He is a CFA charter holder.

Mr. Mars DUAN joined Cenova in 2019 and is primary responsible for project due diligence, project execution and portfolio management. Prior to Cenova, Mr. Duan worked at Duff & Phelps Securities LLC investment banking team and PwC corporate finance team, providing mergers and acquisitions, privatization and financial analysis services to US listed Chinese companies, multi-national companies and private companies across various industries. Mr. Duan also worked at KPMG Shanghai as an assistant manager providing audit services under PRC, IFRS and US GAAP. 

Mr. Duan is CFA charter holder and holds the CPA qualification. He graduated from University of Shanghai for Science and Technology with Bachelor's degrees and Engineering and Accounting. 

Mr. Shenghua Wu joined Cenova in 2018, serving as the Legal Counsel and Compliance Officer of the firm. He has extensive legal and compliance experience in direct investment, and RMB/USD fund formation and operations.

Prior to Cenova, Mr. WU was the Legal Head and Vice President of Hubei River Economic Belt Industry Fund Management Co., Ltd and Shanghai Greenwoods Private Equity Investment Management Co., Ltd. where he was involved in domestic and overseas fund formation, investment, post-investment management and exit. At Clifford Chance LLP (Shanghai Office), Mr. WU trained as a capital markets lawyer where he advised on several domestic and overseas companies shares and bonds listings, and merger and acquisitions.

Mr. WU received his LL. M from Fudan University and his LL.B from Tongji University.    

Ms. Yiying LI has over 30 years of experience in financial management and auditing, particularly in corporate finance, venture capital and private equity. Her domain knowledge includes Chinese GAAP and China’s tax and corporate law. Prior to Cenova, Ms. LI was in charge of investments and portfolio management at Shanghai International Growth Investment Ltd., an investment company listed on the Hong Kong Stock Exchange.

Ms. LI holds a Bachelor in Accounting from the Shanghai University of Finance and Economics. She was also an Associate Professor at Shanghai Lixin University of Commerce and has written many textbooks on finance and accounting.

Ms. Mandy ZHU joined Cenova in 2011.  She has rich experience in fund operation management and government affairs. Mandy's work includes fund architecture management, communication with custodian banks, preparation of financial and custody reports, compliance audit, internal audit and fund compliance reports.

Ms. ZHU has taken part in the establishment of several funds in Cenova. She is usually responsible for communication with the administration for industry and commerce/taxation/commerce commission and other government affairs, as well as capital operation management, etc.

Ms. ZHU graduated from Keele University and got a master of management degree. 

Ms. Lu CHEN joined Cenova in 2017 and is primarily responsible for portfolio management and financial due diligence. Prior to Cenova, she worked at Ping An Group and Evergrande Group in financial and operating analysis, strategy and investor relations. Previously, Ms. CHEN was a Senior Associate at KPMG Shanghai and PwC New York, providing assurance services to various industries including pharmaceuticals, medical equipment, real estate investment trust (“REIT”s) and asset management companies.   

Ms. CHEN holds a Masters in Accounting (Transaction Services) from Wake Forest University and a Bachelor in Economics from Shanghai International Studies University. She is an AICPA and CMA.

Mr. Fuzhou CHEN joined Cenova in 2019 and is primarily responsible for financial & accounting work. Prior to Cenova, he worked at  Deloitte as a Senior Auditor, primarily providing audit service to asset management industry, familiar with the operation of private fund & asset management company and related laws and regulations.

Mr. CHEN holds a Bachelor in Economics from Zhejiang University. He is a CPA and with Legal Professional Qualification Certificate.

Ms. Wen YUAN joined Cenova in 2016 with over 10 years administrative and operating experience in financial services. Ms. Wen YUAN is the treasury manager for USD Fund. She is also responsible for archive management for all funds. Prior to joining Cenova, Ms. Wen Yuan worked as an Executive Secretary at CITIC Capital and as an Administrative Assistant in Morgan Stanley.

Ms. Yuan has a B.A. in Broadcasting and Television and a B.A. in International Economics and Trade from Shanghai University.

Ms. Kelly LI joined Cenova in 2017 as an Office Manager to provide administrative support to the investment team. Previously, she was the Office Manager at Duff and Phelps and has more than ten years of administration experiences in financial and consultancy firms. She is well versed in various aspects of office administration, travel planning, events management and budgetary control. 

Ms. Li graduated with a Bachelor in Hospitality Management from East China Normal University.